Additional HM18 Events

Home/Additional HM18 Events

HM18 Product Theaters

April 9th – 12:15 – 1:15 p.m.

Product Theater #1
Title: Resetting Chronic HF Therapy in Hospitalized Patients with HFrEF
Speaker:
Richard Wright, MD
Chairman of the Board,
Pacific Heart Institute
Santa Monica, California
Sponsored by Novartis Pharmaceuticals

April 9th – 12:15 – 1:15 p.m.

Product Theater #2
Title: The Role of the Hospitalist in Hepatic Encephalopathy
Speaker:
Hameed Q. Ali, DO, FHM
Clinical Assistant Professor
Department of Internal Medicine
Texas A&M Health Science Center
Temple, Texas
Sponsored by Salix Pharmaceuticals

April 9th – 12:15 – 1:15 p.m.

Product Theater #3
Title: Clinical Data and Real-World Evidence to Support NVAF Treatment Decision Making
Speaker:
James F. Neuenschwander II, MD, FACEP
Research Director in the Emergency Department and Attending Physician
Genesis Healthcare Systems
Zanesville, Ohio
Sponsored by Janssen Pharmaceuticals

April 10 – 12:30 – 1:30 p.m.

Product Theater #1
Title: Expert Conversations in Heart Failure: Connecting the Pieces
Speakers:
Thomas Arne, Jr., DO, FACC
Sergey Kachur, MD
Sponsored by Novartis Pharmaceuticals

April 10 – 12:30 – 1:30 p.m.

Product Theater #2
Title: Opioid-Induced Constipation
Speaker: Jeff Gudin, MD
Director, Pain and Palliative Care
Englewood Hospital and Medical Center
Englewood, NJ
Sponsored by Salix Pharmaceuticals

April 10 – 12:30 – 1:30 p.m.

Product Theater #3
Title: Challenges of Treating DVT and PE in the Hospital and After Discharge
Speaker: Dr. Andrew Miller, Emergency Medicine, Lehigh Valley Hospital
Sponsored by Pfizer

HM18 Satellite Symposia

Sunday, April 8, 2018

5:30 – 7:30 p.m. – Canary 1-2

Dinner provided beginning at 5:30

From Hospital Admission to Home: New Standards for Extended Duration VTE Prophylaxis in Acutely Ill Medical Patients

Learning Objective:

To educate on the risk of VTE in acutely ill medical patients, APEX clinical trial results and Bevyxxa (betrixaban)

Program Overview:

  • Review the burden of VTE in acutely ill medical patients
  • Provide an overview of the unmet need for extended-duration VTE prophylaxis from hospital admission to home
  • Review the APEX clinical trial data
  • Provide an overview of Bevyxxa (betrixaban) indication, safety information, dosing and appropriate patient types

Presenter

Hameed Ali, DO, FHM
Clinical Assistant Professor of Medicine and Hospitalist
Baylor Scott and White Health Hospital
Temple, TX

This program is supported by Portola Pharmaceuticals

Sunday, April 8, 2018

5:30 – 7:30 p.m. – Canary 3-4
Dinner provided beginning at 5:30

Reducing COPD-related Readmissions through Individualized Maintenance Therapy and Increased Patient Engagement

Program Overview:

Hospitals are a critical point of intervention in the care pathway of chronic obstructive pulmonary disease (COPD). Clinicians in this setting must be well-versed in current treatment guidelines, as well as the full spectrum of medications and delivery devices, to provide disease management tailored to the physical and cognitive needs of each patient. Moreover, hospital clinicians also need to be adept at communicating with patients and engaging them in the management of their own disease. Collectively, these measures can significantly reduce symptom severity and risk for future exacerbations, increase physical activity, and improve overall quality of life in patients with COPD. This program will improve the knowledge and competence of clinicians who care for patients with COPD.

Learning Objectives:

Upon completion of this educational activity, participants should be able to:

  • Identify long-term treatment strategies to reduce hospital readmissions for COPD exacerbations
  • Review the clinical evidence regarding the efficacy and safety of long-acting maintenance regimens for COPD
  • Select medication delivery devices for patients with COPD based upon individual physical and cognitive characteristics
  • Outline a transitional care plan that promotes patient self-management to reduce the risk for future exacerbations and hospital readmissions

Stanley B. Fiel, MD
Regional Chair, Department of Medicine
Atlantic Health System
The deNeufville Professor
Chairman, Department of Medicine
Morristown Medical Center
Morristown, New Jersey

José Luis González, MD
Assistant Professor of Internal Medicine
Department of Internal Medicine
University of Southern California
Primary Care Physician
Department of Primary Care
LAC+USC Medical Center
Los Angeles, California

Accreditation Info

Accreditation Statement: Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Monday, April 9, 2018

Noon – 1:00 p.m. – Anaheim/Atlanta/Boston

Lunch provided beginning at Noon

A Physician’s Keys to Locking Out Lawsuits and Reducing Taxes

Objectives:

  • Protect your License from negative reports to the NPDB following a settlement from your insurance company. If there is no NPDB report, it’s unlikely that a board investigation into the legal matter will materialize. Preventing any sanctions from the state licensing board.
  • Show how to structure: C-corps, S-corps, FLPs, LLCs, etc.
  • Teach the use of legal tools that will protect their professional and personal assets from lawsuits. (Statistically, not even one in 100,000 are using these tools in the right way.)
  • Learn how to protect business, property, and personal assets in the event of a judgment in excess of liability insurance.
  • Learn how to protect your License from negative reports to the NPDB following a settlement from your insurance company. If there is no NPDB report, it’s unlikely that a board investigation into the legal matter will materialize. Preventing any sanctions from the state licensing board.
  • Learn the best business structure for income tax reduction. Learn how the new tax laws passed in 2017 and how they can benefit you.

Faculty:

Art McOmber

Sponsored by Legally Mine

To register click here

Monday, April 9, 2018

7:30 – 9:30 p.m. – Canary 1-2

Dinner provided beginning at 7:30 p.m.

Community Acquired Bacterial Pneumonia (CABP) in the Hospital Setting: Why Are Patients Not Getting Better?

Program Summary:

Appropriate management of pneumonia in the hospital setting can have a substantial impact on patient outcomes and hospital measures such as readmission rates and length of stay.  Community-acquired bacterial pneumonia (CABP) is one of the most common infectious diseases, one of the most frequent infections requiring antibiotics, and remains a leading cause of death in the United States.  During this presentation, we will review current CABP guidelines from the Infectious Diseases Society of America (IDSA) and discuss the importance of appropriate antibiotic selection as it relates to the tenets of antimicrobial stewardship. The faculty will present two case studies and solicit the audiences’ participation with a focus on antibiotic resistance and the importance of transition of care.

Chair:

William Ford, MD, SFHM
Abington Jefferson Health
Abington, PA

Faculty:

Mauricio Pinto, MD
St. David’s Round Rock Medical Center
Round Rock, TX

Sumeet Shetty, MD, MBA, FHM
Axel Health
Fort Meyers, FL

This program is supported by Nabriva Therapeutics, plc

To Register Contact: NabrivaEvents@HCAGroup.com

Web: www.nabrivaevents.com/SHM/Symposium

Phone: 877-547-5640

Monday, April 9, 2018 

7:30 – 9:30 p.m. – Canary 3-4

Dinner provided beginning at 7:30 p.m.

Direct Oral Anticoagulants (DOACs): Current Evidence for Extended VTE Prophylaxis in Medically Ill Patients and Reversal

Program Overview

Patients hospitalized for an acute medical illness are at an increased risk for VTE. With increasingly shortened hospital stays, acutely ill hospitalized patients are at an increased risk of developing VTE both in the hospital and after discharge. Outpatient VTE episodes often occur within 30 days of hospital discharge and less than half of those discharged patients receive VTE prophylaxis. Therefore, it is important for clinicians to be able to risk stratify patients and provide extended prophylaxis for medical patients at increased risk for VTE.

This symposium will discuss the risk factors and burden of VTE and review ACCP guideline recommendations for VTE prophylaxis in acutely ill hospitalized medical patients. Faculty will assess the safety and efficacy of direct oral anticoagulants for extended VTE prophylaxis, explain the stratification of VTE and bleeding risk, as well as the process for devising evidence-based antithrombotic regimens. The presentation will also include an outline of current and emerging options for reversal of direct oral anticoagulants.

Learning Objectives

  • Outline the risk factors and burden of VTE in medically ill patients post-hospitalization
  • Review ACCP and ASH guideline recommendations for VTE prophylaxis in acutely ill hospitalized medical patients
  • Assess the safety and efficacy of direct oral anticoagulants (DOACs) for extended VTE prophylaxis in medically ill patients
  • Devise evidence-based antithrombotic regimens for medically ill patients taking into consideration patient specific factors that impact VTE and bleeding risk
  • Outline current and emerging options for reversal of DOACs

Faculty:

Amir K Jaffer, MD, MBA
Chief Medical Officer
New York Presbyterian Queens Hospital
New York, NY

Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Professor of Medicine,
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
System Director – Anticoagulation and Clinical Thrombosis Services
Northwell Health at Lenox Hill Hospital
New York, NY

Alan Jacobson, MD, FACC
Assistant Professor of Medicine
Loma Linda University School of Medicine
Director of Anticoagulation Services
Loma Linda VA Medical Center
Loma Linda, California

Target Audience

Hospitalists, internists, nurse practitioners (NPs), physician assistants (PAs) who practice in a hospital setting.

Credit Designation

Horizon CME designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

ABIM MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Supporter Statement:

This activity is supported by an independent educational grant from Portola Pharmaceuticals.

Register Online:

http://bit.ly/2EoP1tb

Tuesday, April 10, 2018

7:30-9:30 p.m. – Canary 1-2

Dinner provided beginning at 7:30 p.m.

Valuable Strategies to Reduce the Risk for and Clinical Impact of Hyperkalemia

Program Overview

The goal of the case-based symposium is to highlight patients at increased risk of recurrent or sustained hyperkalemia and how these patients may be managed with evidence-based treatment so that they are able to continue renin-angiotensin-aldosterone system inhibitor therapy, if appropriate. Drs. Biff Palmer and Robert Toto will share their experiences in managing these patients, including suggestions for the hospitalist’s role in continued care.

Biff F. Palmer, MD
Professor of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Robert Toto, MD
Associate Dean, Clinical and Translational Research
Director, Center for Translational Medicine
UT Southwestern Medical Center
Dallas, Texas

Accreditation

This activity has been approved for AMA PRA Category 1 Credit(s)™.

See final CE activity announcement for specific details.

This activity is supported by an educational grant from Relypsa, Inc.

Tuesday, April 10, 2018

7:30-9:30 p.m. – Canary 3-4

Registration will be at 7:00 p.m.

Dinner provided beginning at 7:30 p.m.

Hepatology News Tonight: Managing Complications of Cirrhosis

Program Description

This educational update will highlight the most clinically relevant advances in the management of patients with Cirrhosis and Hepatic Encephalopathy (HE). The symposium will deliver emerging science and incorporate expert opinions on best practices for the diagnosis and management of patients with Cirrhosis and HE.

Target Audience

This activity has been designed to meet the educational needs of physicians, advanced practice providers and allied health professionals who provide care for hospitalized patients with liver disease.

Learning Objectives

  • Understand the complications and the consequences of chronic liver disease
  • Describe the economic, patient and caregiver burdens associated with cirrhosis and HE
  • Demonstrate the ability to properly treat HE patients and prevent recurrence of disease

Faculty

Naoky Tsai, MD
Clinical Professor of Medicine
John A. Burns School of Medicine
University of Hawaii, Manoa
Honolulu, Hawaii

Ashwani K. Singal MD, MS, FACG, FAASLD
Associate Professor of Medicine and Director UAB Porphyria Center
Division of Gastroenterology and Hepatology
University of Alabama at Birmingham
Birmingham, Alabama

Name of sponsoring organization/company providing the educations grant:

Accredited by:

Rehoboth McKindley Christian Health Care Services

Provided by:

CLDF
Chronic Liver Disease Foundation

Supported by an educational grant from Salix Pharmaceuticals

Register Online:

http://www.chronicliverdisease.org/